aroxybutynin
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started Oct 27, 2020 (NCT04580394)
Timeline
Indications
Studied for
Mechanism of action
- Muscarinic acetylcholine receptor M2INHIBITOR
CHRM2 inhibitor
- Muscarinic acetylcholine receptor M3INHIBITOR
CHRM3 inhibitor
- Muscarinic acetylcholine receptor M1INHIBITOR
CHRM1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCN(CC)CC#CCOC(=O)[C@](O)(c1ccccc1)C1CCCCC1- Mol. weight
- 357.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL185434 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06566820 | Phase 3 | Jul 3, 2024 | Apnimed, Inc. |
| NCT06400615 | Phase 2 | May 20, 2024 | Apnimed, Inc. |
| NCT05813275 | Phase 3 | Sep 16, 2023 | Apnimed, Inc. |
| NCT05811247 | Phase 3 | Aug 28, 2023 | Apnimed, Inc. |
| NCT05071612 | Phase 2 | Dec 15, 2021 | Apnimed, Inc. |
| NCT04631107 | Phase 2 | Dec 31, 2020 | Apnimed, Inc. |
| NCT04580394 | Phase 2 | Oct 27, 2020 | Apnimed, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Apnimed, Inc. | For profit | 7 | 7 | 2 | 2020 |
1 organizations
Page 1 / 1